SecBot SecBot
SECBOTREPLAY Home › Report › ANAB

ANAB · AnaptysBio reported strong Q4 and full-year 2025 financial results…

AnaptysBio, Inc. · PRESS-RELEASE filed Mar 3, 2026 at 16:15 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 3, 2026 at 16:15 ET

AnaptysBio reported strong Q4 and full-year 2025 financial results driven by a surge in Jemperli royalties and milestones from GSK, including a $75M milestone payment. Collaboration revenue more than doubled, and the company confirmed progress toward a Q2 2026 spin-off of its biopharma assets into First Tracks Biotherapeutics. Despite a net loss for the year, cash remains robust at $311.6M, and the royalty outlook is bullish with >$390M in annualized royalties expected by 2029.

  • Collaboration revenue was $108.2M (Q4) and $234.6M (full year 2025), up from $43.1M and $91.3M in 2024.
  • Jemperli achieved $1B in global sales in Nov 2025, triggering a $75M milestone payment to Anaptys.
  • Jemperli royalties grew 103% YoY to $96.0M for the year, with a $1.4B annualized run rate in Q4.
  • Anaptys expects >$390M in annualized Jemperli royalties by 2029 at GSK's peak sales guidance of >$2.7B.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access